Realbotix draws additional USD 500,000 under Onconetix bridge loan
ONCO•A Realbotix subsidiary drew an additional USD 500,000 from Onconetix, bringing total advances under the USD 5 million facility to USD 3 million. The unsecured, non-interest-bearing note is to be canceled if the proposed merger closes; if the merger agreement terminates, outstanding principal accrues 12% annual interest from that date.
1. Additional loan advance
Realbotix's wholly owned subsidiary agreed to an additional USD 500,000 advance from Onconetix for working capital ahead of their proposed merger. The draw raises total advances to USD 3 million under the USD 5 million facility.
2. Repayment terms
Under a September 14, 2026 agreement, the advance is documented by an unsecured, non-interest-bearing promissory note guaranteed by Realbotix. If the merger closes, the note will be canceled and all loan obligations discharged without payment; if the merger agreement terminates, outstanding principal will accrue 12% annual interest from the termination date.
